Participated · Series A · Sep 2025

Penguin Ai’s flagship platform combines task-specific Small Language Models (SLMs), proprietary language models, APIs and out-of-the-box Digital Workers and Agents to automate back-office healthcare workflows such as medical coding, prior authorizations, claims adjudication, appeals management, risk adjustment, chart summarization and payment integrity. The company emphasizes a full-service platform approach rather than point solutions, including tooling to prepare data for AI, pre-built healthcare LLMs, and governance and bias-correction capabilities for security and fairness. Penguin Ai says it has secured key partnerships with health plans, providers and technology organizations and is collaborating with customers to accelerate development of its enterprise-grade platform. Leadership is led by founder and CEO Fawad Butt, the former chief data officer of UnitedHealthcare, Kaiser Permanente and Optum, and the team brings collective experience from major payer, provider and tech organizations. The company positions its technology to reduce the industry’s estimated $1 trillion administrative burden and to lower operational costs while improving accuracy and efficiency. Penguin Ai plans to use recent funding to support hiring, product development, and scaling deployments with payers and providers.

Participated · Series E · Jan 2025

Solera Health operates the HALO platform, a marketplace that connects payers, employers, and individuals to clinically validated digital health applications and turnkey programs. The company plans to expand the Solera HALO platform by building the HALO Cloud to unite its network of point solutions and simplify integration of hundreds of digital health applications. Solera has recently added virtual specialty care and solutions targeting cardiometabolic conditions such as hypertension, high cholesterol, diabetes prevention, and weight management. It also announced a strategic collaboration with professional services firm Aon to enable employers to deliver personalized health experiences and engage high-risk employees. Leadership changed when John Santelli, who joined in March 2024, transitioned from interim CEO to chief executive officer and intends to deepen integration into customers’ operations. Financially, Solera announced $40 million in new funding to support product expansion and operational scaling of its HALO technology and services. Solera Health is a Phoenix, AZ-based platform that supports an ecosystem of community and digital partners matching health plan members to chronic disease prevention and management, social determinants of health (SDOH) and behavioral health. Led by CEO Brenda Schmidt, the company serves as an integrated benefit network that connects patients, payers and physicians with community organizations and digital therapeutics providers. Solera consolidates fragmented programs and services into a single marketplace, allowing health plans and medical providers to increase consumer participation while lowering associated costs. The company raised $42M in Series C financing, bringing total funding to date to $72M. It intends to use the funds to address behavioral health and SDOH needs such as food insecurity, medically tailored meals, transportation, falls prevention and social isolation. Over the past 12 months Solera has expanded its network to support a broader array of lifestyle modification programs, including diabetes management, hypertension, stress, sleep, tobacco cessation and weight management. Solera Health provides integrated chronic disease prevention services that connect patients, payers and physicians with community organizations and digital therapeutics providers. It consolidates fragmented programs and services into one integrated network to increase consumer participation and lower associated costs for health plans and medical providers. Solera has built a national network of community organizations and digital DPPs including Weight Watchers, Lark, Retrofit and Noom. Since launch the company has grown to over 70 employees and has over 40 million covered lives under contract. Led by CEO Brenda Schmidt and based in Phoenix, AZ, Solera intends to use the new funding to expand its offering and business reach. The company has raised $30.3M in total to date. Solera Health is a technology-enabled personalized preventive health network that operates a marketplace connecting U.S. adults at risk for type 2 diabetes with CDC-recognized Diabetes Prevention Programs (DPPs). Led by CEO Brenda Schmidt and based in Phoenix, AZ, the company aggregates more than 850 digital, national, and community-based DPPs into one integrated network. Its national model was designed to consolidate fragmented programs and services to increase consumer access and participation while lowering associated costs for health plans and medical providers. Strategic partnerships include HealthSlate, Blue Mesa Health, Noom, Retrofit, Canary Health, Weight Watchers and organizations such as the Black Women Health Imperative. The company has raised $7M in total funding and recently closed a $4M Series A1 round. Solera will use the new funds to scale operations for the National DPP as a covered health benefit. Solera Health operates a proprietary SaaS platform that connects a national network of local community organizations and digital solutions to deliver chronic disease prevention programs. The platform supports administration and streamlining of National Diabetes Prevention Program (DPP) referrals, reimbursement and payment management, and aggregation of data and reporting. Its services simplify enrollment and support consumer engagement and choice for DPP offerings led by the CDC. The company is led by founder and CEO Brenda Schmidt and is based in Phoenix, AZ. Solera positions itself as a technology-enabled integrator across local and digital program providers to increase access to prevention services. It plans to use recent funding to advance its technology platform and scale operations.

Led · Series A · Oct 2024

CredibleMind provides a platform that scans, organizes, and AI-personalizes tens of thousands of expert-curated resources across over one hundred mental health topics. The platform creates individualized digital experiences that blend evidence-based self-care and validated assessments with health plan programs and care network resources. CredibleMind aims to engage members, reduce access barriers, and deliver expert-backed guidance on effective care and support. The company plans to use new funding to accelerate growth in its Health Plan and Public Health businesses and to further develop its AI-infused data engine. That AI-infused data engine is intended to improve resource curation, consumer activation, care navigation, and to advance quality and care outcomes. CredibleMind has rapidly expanded to reach over 30 million lives nationwide and has a presence among major health plans and over 100 communities across the U.S.

Participated · Series B · Mar 2020

Pager operates a virtual care collaboration platform that combines AI automation with concierge services to deliver a whole-person healthcare experience. Its solution integrates triage, telemedicine, e-prescriptions, appointment scheduling, after-care follow-up, care advocacy, and customer service within an omni-channel communications interface. The platform aggregates nurses, doctors, pharmacists, coordinators, and advocates so that users can access an end-to-end care journey in one place. Pager works with payers, providers, and employers that collectively cover more than 15 million people across the United States and Latin America. The company is expanding its enterprise offering, Pager 360, which supports cross-functional care teams and is distributed through health plans, provider systems, and employers. Fresh capital will be allocated to scaling capacity for rising demand, accelerating product innovation, and entering additional U.S., Latin American, and global markets. Pager is headquartered in New York City and is led by CEO and Chairman Walter Jin.

Participated · Series C · Feb 2018

Cota is a New York-based company led by CEO Miruna Sasu that provides oncology real-world data (RWD) and analytics using technology-supported human data abstraction methods. Its core product is an RWD platform and services that organize complex, fragmented patient data to support cancer research and drug development. The company expanded its data platform to cover nearly 2 million cancer patient lives, quadrupling data access in two years and adding full genomic data. Cota is integrating emerging data types including clinicogenomics, social determinants of health, and sexual orientation and gender identity (SOGI). It launched Vantage, a product that gives subscribers real-time access to broad, curated datasets that are proactively refreshed. The company also introduced services to support life sciences companies with FDA and EMA drug submissions, integrating RWD in R&D, enabling HEOR, and informing market-access strategies. Cota received an investment from Deerfield Management and existing investors; the amount was not disclosed, and the funds will be used to further expand its RWD platform and services to drive more efficient and inclusive drug development. Cota builds real-world evidence and data analytics products powered by its patented Cota Nodal Address (CNA), a digital classification methodology developed by physicians and data scientists to precisely categorize patient factors, diseases and therapies. The company enriches medical records to create research-grade data and pairs those datasets with analysis, visualization and management tools. Its real-world evidence sets are used by life science companies to broaden clinical trial applicability, improve measured efficacies and lower trial costs. Cota serves healthcare providers, payers and life sciences customers and intends to scale those solutions across those segments. The company is led by CEO John Hervey and executive chairman Andrew Pecora, M.D. Financially, Cota completed a $40M Series C to support its scaling plans. Cota builds research‑grade, real‑world data and precision analytics to measure cancer treatment outcomes using its patented Cota Nodal Address (CNA) digital classification system. The CNA transforms prognostically significant variables into a digital code to precisely categorize patient factors, diseases, and therapies for benchmarking, research, and value‑based care. Its customers include pharmaceutical companies, healthcare providers, and insurance companies, and it has partnerships with Novartis, Celgene, and data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine, and Horizon Healthcare. Cota’s CEO, Eric Schultz, says the company has seen strong revenue growth and rapid adoption of its products across multiple markets. A. Dana Callow, Jr. of Boston Millennia Partners is joining Cota’s board to provide guidance across provider, payer, life sciences, and regulatory environments. COTA (Cancer Outcomes Tracking and Analysis) operates a cloud-based platform that aggregates cancer patient data and performs real-time genetic sorting of certain cancers while providing outcome tracking and reporting to physicians. The platform aims to help tailor therapy decisions—for example, identifying breast cancer subtypes where chemotherapy is unlikely to help—thereby potentially reducing unnecessary treatment and costs. COTA plans to use new funding to expand development of its platform and to hire biostatisticians, outcome analysts, data support, and sales and marketing staff. The company intends to launch its first commercial product with the raised capital. Prior to this Series A, COTA received a seed round from private sources and RCCA, one of the largest oncology groups in the country.